Widjaja Sry Suryani, Ichwan Muhammad, Chowbay Balram, Mardani Tengku Helvi, Jayalie Vito Filbert
Department of Biochemistry, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia.
Department of Pharmacology, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia.
J Adv Pharm Technol Res. 2024 Jul-Sep;15(3):135-138. doi: 10.4103/JAPTR.JAPTR_69_24. Epub 2024 Jul 22.
Acute pain, moderate-to-severe cancer pain, and persistent malignant pain are all frequently treated with opioids. It is regarded as one of the main tenets of analgesic treatment. The relationship between human opioid sensitivity and genetic polymorphism differences has received little attention up to this point in research. Nonetheless, there is mounting proof that pharmacogenomic diversity could affect how each person reacts to opioids. Finding out how gene polymorphism affects analgesic use is the aim of this investigation, particularly opioids. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses standards were followed in the preparation of the systematic review approach used in this work. Oxycodone, fentanyl, raclopride, tramadol, ketorolac, morphine, ropivacaine, levobupivacaine, subfentanyl, remifentanil, and nortriptyline were the opioid medications used in the study, which was based on 13 publications. From those articles, we reviewed the impact of gene polymorphism on pain management and drug pharmacokinetics. Based on this systematic review, we concluded that gene polymorphism of gene affects analgesic, specifically opioid mechanisms.
急性疼痛、中重度癌痛和持续性恶性疼痛通常都用阿片类药物治疗。这被视为镇痛治疗的主要原则之一。到目前为止，人类阿片类药物敏感性与基因多态性差异之间的关系在研究中很少受到关注。然而，越来越多的证据表明，药物基因组多样性可能会影响每个人对阿片类药物的反应。本研究的目的是了解基因多态性如何影响镇痛药物的使用，特别是阿片类药物。本研究采用的系统评价方法是按照系统评价和Meta分析的首选报告项目标准制定的。本研究基于13篇文献，使用的阿片类药物有羟考酮、芬太尼、雷氯必利、曲马多、酮咯酸、吗啡、罗哌卡因、左旋布比卡因、亚芬太尼、瑞芬太尼和去甲替林。从这些文章中，我们综述了基因多态性对疼痛管理和药物药代动力学的影响。基于这项系统评价，我们得出结论，基因的多态性会影响镇痛效果，特别是阿片类药物的作用机制。
